



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 7, 2020

Steven C. Quay
Chairman, Chief Executive Officer and President
Atossa Therapeutics, Inc.
107 Spring Street
Seattle, Washington 98104

Re: Atossa Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 2, 2020
File No. 333-248555

Dear Dr. Quay:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Ryan A. Murr, Esq.